Either way, you want a real answer
Despite the minority of people for whom these drugs dont work, their introduction promises to provide significant health benefits to millions of people who have previously struggled to lose weight.
Moderate harm events like cholelithiasis (RR 1.90) and alopecia (5.67) were higher among GLP-1 RA users, with tirzepatide specifically associated with alopecia
Patients should contact their GP or prescribing clinician if they experience : Sudden onset of skin changes disproportionate to weight loss Areas of skin that appear abnormally thin, fragile, or prone to tearing Easy bruising or poor wound healing Development of striae (stretch marks) during weight loss rather than weight gain Skin changes accompanied by other symptoms such as muscle weakness, fatigue, or mood disturbances Purple/wide striae with easy bruising and proximal muscle weakness (which may suggest Cushing's syndrome) Seek same-day care or emergency help for severe allergic reactions, rapidly spreading rash, or unexplained extensive bruising or bleeding
Monitoring and gradual transitions help
Nonetheless, considering the clinical relevance of GLP-1 therapies and their potential impact on energy balance beyond food intake and body weight, future studies should investigate whether GLP-1 agonists influence hypothalamic neuropeptide expression or signaling cascades in MC4R-deficient models